Key result
Implementation of an ERAS protocol reduced length of stay after cytoreductive surgery with HIPEC (MD -3.17; 95% CrI -4.68 to -1.69) and CRS alone (MD -1.65; 95% CrI -2.32 to -1.06).
Why the study?
The safety and efficacy impact of enhanced recovery after surgery programs in the treatment of peritoneal surface malignancies remained unclear.
Does an ERAS program reduce length of stay and postoperative complications in patients undergoing cytoreductive surgery with or without HIPEC for peritoneal metastases?
Meta-Analysis (n=5,131)
Yes
Does an ERAS program reduce length of stay and postoperative complications in patients undergoing cytoreductive surgery with or without HIPEC for peritoneal metastases?
Mean Difference: -3.17 (95% CI -4.68–-1.69)
Implementation of an ERAS protocol reduces length of stay and postoperative complications after cytoreductive surgery with or without HIPEC compared to conventional recovery.
Supports ERAS adoption to shorten LOS after CRS ± HIPEC; extends benefits from colorectal and other major oncologic surgeries to peritoneal malignancies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Robella et al. (2023) conducted a meta-analysis in Peritoneal surface malignancies (n=5,131). Enhanced Recovery after Surgery (ERAS) program vs. conventional recovery was evaluated on postoperative length of stay (LOS) (MD -3.17, 95% CI -4.68 to -1.69). Implementation of an ERAS protocol reduced length of stay after cytoreductive surgery with HIPEC (MD -3.17; 95% CrI -4.68 to -1.69) and CRS alone (MD -1.65; 95% CrI -2.32 to -1.06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: